KRT8 Antikörper

Produktnummer ABIN965966

Der Maus-Monoklonal Anti-KRT8-Antikörper wurde für IHC (p) und IHC (fro) validiert. Er ist geeignet zum Nachweis von KRT8 in Proben aus Human. }

Kurzübersicht für KRT8 Antikörper (ABIN965966)

Target: KRT8 (Keratin 8 (KRT8))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser KRT8 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: B391

Produktdetails anti-KRT8 Antikörper

Aufreinigung: Concentrated.

Immunogen: Cytoskeleton preparation from HeLa Cells

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Immunohistochemistry: (Paraffin/Frozen): 1:50 -1:100.
Staining Procedure: Prolonged fixation in buffered formalin can destroy the epitope. The antibody may be used at a dilution of 1:50 to 1:100 with AutoProbe III. The optimal conditions should be determined by the individual laboratory. The Auto/Zyme predigestion or high temperature antigenic unmasking technique is recommended with this antibody when using paraffinembedded tissue sections.

Kommentare:

Cellular Localization: Cytoplasm.
Recommended Positive Control: Colon, Lung, or Breast Carcinomas

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 35 mg/ml

Buffer: 20 mM Tris-Borate, 150 mM Sodium Chloride, dialyzed media RPMI 1640/D-MEM containing Fetal Bovine Serum, BMC-6 Carrier Polysaccharides, Carrier Protein, pH 7.5

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Details zu KRT8

Target: KRT8 (Keratin 8 (KRT8))

Andere Bezeichnung: Cytokeratin 8 (52.2 kDa)

Hintergrund: This antibody reacts with Cytokeratin 8 (52 and 45 kD) human polypeptide. This cytokeratin coexists With Cytokeratin 18 and is found in all non-squamous epithelium but not in squamous epithelium. It Reacts with the adenocarcinomas of ovary, gastrointestinal tract, prostate, and thyroid.